Cerus Corp - CERS STOCK NEWS

Cerus Corporation (NASDAQ: CERS) will release its third quarter 2022 financial results on November 3, 2022, after market close. A conference call and webcast will be held at 4:30 P.M. ET that day, where management will discuss financials and business outlook. The event can be accessed via the Cerus Investor Relations page. A replay will be available approximately three hours post-call until November 17, 2022. The company focuses on safeguarding the blood supply with its INTERCEPT Blood System, which is FDA approved for platelets and plasma.

Cerus Corporation (Nasdaq:CERS) reported its participation in the 2022 AABB Annual Meeting in Orlando, FL from October 1-4. This marks the conference's first in-person event since 2019. Cerus will present several abstracts highlighting the benefits of the INTERCEPT Blood System for Platelets and Cryoprecipitation. Key presentations include a plenary session on platelet safety and storage and a dedicated industry workshop. The INTERCEPT systems are pivotal for pathogen reduction in blood products and have received both CE mark and FDA approval.

Cerus Corporation (NASDAQ: CERS) acknowledges the U.S. Department of Health and Human Services' declaration of monkeypox as a national Public Health Emergency, with over 10,000 reported cases in the U.S. and 30,000 globally. The company highlights its INTERCEPT Blood System, which has been effective in inactivating a broad spectrum of pathogens, including the vaccinia virus, a close relative of monkeypox. This technology provides essential support in safeguarding the blood supply against emerging infectious diseases, ensuring blood safety and availability during outbreaks.

Cerus Corporation (Nasdaq: CERS) reported record product revenue of $41.0 million for Q2 2022, a 30% year-over-year increase, contributing to total revenue of $47.6 million, up 26% compared to the previous year. The company reiterated its full-year product revenue guidance of $160-165 million, reflecting a 22%-26% growth. Despite a net loss of $8.4 million, improved expense management led to a better financial position with cash reserves of $107 million. The INTERCEPT Blood System has surpassed 12 million treatable doses globally.

Cerus Corporation (CERS) will release its second quarter 2022 financial results on August 4, 2022, post-market. A conference call is scheduled for 4:30 PM ET to discuss the results and business outlook. The company focuses on safeguarding the global blood supply, with its INTERCEPT Blood System approved for platelets and plasma. The red blood cell system is undergoing regulatory review in Europe and clinical development in the US. A replay of the call will be available on the company's website.

Cerus Corporation (NASDAQ: CERS) announced the appointment of Dr. Hua Shan to its Board of Directors. Dr. Shan, a renowned expert in transfusion medicine with over 25 years of experience, aims to enhance Cerus' efforts in the Chinese market for its INTERCEPT Blood System. The Board Chair, Daniel Swisher, expressed confidence that Dr. Shan's extensive knowledge will positively impact Cerus' global presence and product safety initiatives. Dr. Shan previously served in key roles at prestigious institutions, including Stanford Medical Center and Johns Hopkins University.

Cerus Corporation (CERS) reported a strong first-quarter 2022 performance with total revenue of $43.0 million, reflecting a 46% year-over-year increase. Product revenue reached $37.4 million, up 60% year-over-year. The company improved its 2022 product revenue guidance to a range of $160-165 million, a 22%-26% increase over 2021. Net loss decreased to $12.3 million from $17.5 million the previous year. Notable contracts include a multi-year agreement with the American Red Cross for INTERCEPT Platelet kits, reinforcing strong demand in the U.S.

Cerus Corporation has secured a ten-year deal with Fresenius Kabi to produce INTERCEPT Blood System sets, replacing the current contract that expires in July 2025. This collaboration aims to meet increasing global demand and enhance supply chain reliability. Manufacturing will expand to new facilities in the Caribbean and continue in France, ensuring redundancy and higher production volumes. This partnership is expected to deliver significant benefits for customers and shareholders, reinforcing Cerus' commitment to pathogen reduction in transfusion medicine.